ReviewClinical cardiology2000
Chagas' heart disease.
Review in Clinical cardiology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Pooled it
- Trial
- Trial
- Barriers to Chagas Disease Screening among Primary Care Providers in the United States.The American journal of tropical medicine and hygiene · 2026Article
- From Detection to Motion-Based Classification: A Two-Stage Approach forJournal of imaging · 2025Article
- Beyond Mosquitoes: A Review of Pediatric Vector-Borne Diseases Excluding Malaria and Arboviral Infections.Pathogens (Basel, Switzerland) · 2025Review
- PBMC transcriptomic signatures reflect Trypanosoma cruzi strain diversity and trained immunity in chronically infected macaques.JCI insight · 2025Article
- New parameter for QRS complex low voltage in chagasic cardiomyopathy: the ADOC index.Revista da Sociedade Brasileira de Medicina Tropical · 2025Article
- Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model.Vaccines · 2024Article
- Chagas Disease Diagnosis withVaccines · 2024Article
- Unraveling the Missing Pieces: Exploring the Gaps in Understanding Chagas Cardiomyopathy.Cureus · 2024Review
- Chagas Disease: Comparison of Therapy with Nifurtimox and Benznidazole in Indigenous Communities in Colombia.Journal of clinical medicine · 2024Article
- Cardiac Abnormalities in a Predictive Mouse Model of Chagas Disease.Pathogens (Basel, Switzerland) · 2023Article
- Detection of Early Diffuse Myocardial Fibrosis and Inflammation in Chagas Cardiomyopathy with T1 Mapping and Extracellular Volume.Radiology. Cardiothoracic imaging · 2023Article
- Successful ablation of ventricular tachycardia in a patient with Chagas disease using ethanol ablation in the coronary venous system: A case report.HeartRhythm case reports · 2023Article
- Chagas disease-induced ventricular tachycardia: A case report.Global cardiology science & practice · 2023Article
- Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure.Journal of clinical medicine · 2022Review
- Early identification of patients with Chagas disease at risk of developing cardiomyopathy using 2-D speckle tracking strain:International journal of cardiology. Heart & vasculature · 2022Article
- Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease.PLoS neglected tropical diseases · 2021Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas' disease is caused by a protozoan parasite, Trypanosoma cruzi, that is transmitted to humans through the feces of infected bloodsucking insects in endemic areas of Latin America, or occasionally by nonvectorial mechanisms, such as blood transfusion. Cardiac involvement, which typically appears decades after the initial infection, may result in cardiac arrhythmias, ventricular aneurysm, congestive heart failure, thromboembolism, and sudden cardiac death. Between 16 and 18 million persons are infected in Latin America. The migration of infected Latin Americans to the United States or other countries where the disease is uncommon poses two problems: the misdiagnosis or undiagnosis of Chagas' heart disease in these immigrants and the possibility of transmission of Chagas' disease through blood transfusions. Diagnosis is based on positive serologic tests and the clinical features. The antiparasitic drug, benznidazole, is effective when given for the initial infection and may also be beneficial for the chronic phase. The use of amiodarone, angiotensin-converting enzyme inhibitors, and pacemaker implantation may contribute to a better survival in selected patients with cardiac involvement of chronic Chagas' disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.